Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1B-408 in Women With Orgasmic Dysfunction
NCT06516055Phase 2Not yet recruiting
- Sponsor
- S1 Biopharma
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of S1B-408, sponsored by S1 Biopharma. Primary endpoint: Female Sexual Function Index: orgasm domain at 28 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
S1B-408
Beyond the preview
Go deeper on NCT06516055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516055.